Experimentica Ltd., a global contract research organization (CRO) dedicated to preclinical models of ophthalmic diseases, today announced a significant expansion of its Kuopio site. This strategic development includes the establishment of additional in vivo laboratory facilities and a corresponding increase in operational capacity.

The expansion marks a critical step in the company’s growth trajectory towards becoming an end-to-end preclinical partner in drug discovery and toxicology for research teams developing new drugs and medical devices in Ophthalmology.

"This investment supports new business opportunities and underpins our long-term development as a trusted international CRO partner."

Jukka Puoliväli, Managing Director,

Experimentica Ltd.

Expanding in vivo capabilities

A key scientific advancement in this expansion is the introduction of rabbit models at the Kuopio site. This addition complements the facility’s existing rodent (rat and mouse) platforms, offering a more comprehensive suite of translational tools. It also complements the already existing offer of efficacy and toxicology models in rabbits provided by Experimentica‘s Vilnius, Lithuania site. By broadening its species portfolio and bandwidth, Experimentica aims to meet the increasing global demand for sophisticated preclinical Ophthalmology studies that require diverse biological systems for validation.

“The expansion of our Kuopio site is an important milestone in Experimentica’s growth strategy. With the laboratory setup already in progress and new team members joining early in the year, we are strengthening our in vivo Ophthalmology capabilities across species and creating a strong foundation for future growth,” stated Jukka Puoliväli, Managing Director of Experimentica Ltd.

“Our clients are increasingly seeking streamlined pathways from early discovery to regulatory submission. Expanding our Kuopio facility to include rabbit models and provide shorter timelines is one of several commitments Experimentica is currently making to bridge the gap between initial rodent efficacy data and the complex safety profiles required for human trials. This is about providing a seamless service that accelerates the development of our clients‘ novel ocular therapies,” commented Guillaume Demarne, Chief Business Officer at Experimentica Ltd.

This expansion is co-funded by the European Union.

About Experimentica Ltd.

Experimentica Ltd. is a leading contract research organization dedicated to developing and managing preclinical models for ophthalmic indications. With proprietary laboratories in Kuopio, Finland and Vilnius, Lithuania, and an industry-leading portfolio, the company supports the discovery and development of new therapies by offering comprehensive research solutions to the pharmaceutical and biotech companies.

Media contact

Anu Finne
Marketing and Business Development Specialist
email: bd@experimentica.com

Anu Finne

Anu Finne

Marketing and Business Development Specialist